Chief Medical Officer

Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025

Spyre Therapeutics Completes $316 Million Public Offering

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million

Spyre Therapeutics Closes $316.2 Million Public Offering

Executive Medical Director, Clinical Development

Spyre Therapeutics is a clinical-stage biotechnology company focused on developing innovative products for inflammatory bowel disease (IBD) and other immune-mediated diseases. The Executive Medical Director, Clinical Development will lead IBD studies and collaborate across functions to ensure successful clinical program execution while providing strategic leadership and medical expertise.

Sign up with Google

Sign in with Google